Global Dihydrocodeine Market

Dihydrocodeine Comprehensive Study by Application (Cough Suppressant, Analgesic), Route of Administration (Oral, Injection) Players and Region - Global Market Outlook to 2028

Dihydrocodeine Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Dihydrocodeine Market Overview:
Dihydrocodeine (DHC) is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It can also be used to treat chronic pain, breathlessness, and coughing. In heroin addicts, dihydrocodeine has been used as a substitute drug, in doses up to 2500mg/day to treat addiction. DHC is used as an analgesic and antitussive agent and for the management of dyspnea and opioid addiction.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
High Demand for Dihydrocodeine with Improved Feature

Market Growth Drivers:
Increase in Healthcare Expenditure and High Adoption in Case of Severe Pain, Severe d=Dyspnea, and Cough

Challenges:
Growing Number of Regulatory Approvals

Restraints:
Side Effects Associated With the Dihydrocodeine

Opportunities:
High Demand For Innovative Treatment Techniques and Technological Advancements in the Field Of Medical Science

Competitive Landscape:
The competition in the market is strong. There is a maximum no of companies who manufactures these medications that’s why there is a rivalry between top firms. Some companies, therefore, relying on mergers and acquisitions are an option to earn more business and catch the market.
Some of the key players profiled in the report are Teofarma (Italy), Mundipharma (United Kingdom), Napp Pharmaceuticals (United Kingdom), Aspen Pharmacare (South Africa), Martindale-Hubbell (United States), Duopharma Biotech Berhad (Malaysia), Wockhardt (India), Auden Mckenzie Pharma (United Kingdom), WraSer (United States) and GlaxoSmithKline (United Kingdom). Additionally, following companies can also be profiled that are part of our coverage like G.L. Pharma (Austria), Daiichi Sankyo (Japan) and Fuso Pharmaceutical (Japan). Analyst at AMA Research see Global Players to retain maximum share of Global Dihydrocodeine market by 2028. Considering Market by Route of Administration, the sub-segment i.e. Oral will boost the Dihydrocodeine market.

Latest Market Insights:
In October 2023, Zydus Cadila, a leading Indian pharmaceutical company, announced a collaboration with the University of California, San Diego, to develop a novel non-opioid pain management therapy. While the specific drug doesn't involve dihydrocodeine, this partnership highlights the ongoing search for alternative pain relief options.

In September 2023, Mallinckrodt Pharmaceuticals, a US-based specialty pharmaceutical company, partnered with the American Society of Addiction Medicine (ASAM) to launch an educational campaign on the safe and responsible use of opioid medications. This initiative aims to address the ongoing opioid crisis and promote responsible prescribing practices.

FDA announced new regulation for prescription opioid cough and cold medicines to limit their use to adults 18 years and older The U.S. Food and Drug Administration (FDA) is requiring safety labeling changes for prescription cough and cold medicines containing codeine or hydrocodone to limit the use of these products to adults 18 years and older because the risks of these medicines outweigh their benefits in children younger than 18. They also require the addition of safety information about the risks of misuse, abuse, addiction, overdose, death, and slowed or difficult breathing to the Boxed Warning.

What Can be Explored with the Dihydrocodeine Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Dihydrocodeine Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Dihydrocodeine
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Dihydrocodeine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Dihydrocodeine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Dihydrocodeine Manufacturers, Suppliers, and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Application
  • Cough Suppressant
  • Analgesic
By Route of Administration
  • Oral
  • Injection

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Healthcare Expenditure
      • 3.2.2. High Adoption in Case of Severe Pain, Severe d=Dyspnea, and Cough
    • 3.3. Market Challenges
      • 3.3.1. Growing Number of Regulatory Approvals
    • 3.4. Market Trends
      • 3.4.1. High Demand for Dihydrocodeine with Improved Feature
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dihydrocodeine, by Application, Route of Administration and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Dihydrocodeine (Value)
      • 5.2.1. Global Dihydrocodeine by: Application (Value)
        • 5.2.1.1. Cough Suppressant
        • 5.2.1.2. Analgesic
      • 5.2.2. Global Dihydrocodeine by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Injection
      • 5.2.3. Global Dihydrocodeine Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Dihydrocodeine (Price)
  • 6. Dihydrocodeine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teofarma (Italy)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Mundipharma (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Napp Pharmaceuticals (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Aspen Pharmacare (South Africa)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Martindale-Hubbell (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Duopharma Biotech Berhad (Malaysia)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Wockhardt (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Auden Mckenzie Pharma (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. WraSer (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Dihydrocodeine Sale, by Application, Route of Administration and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Dihydrocodeine (Value)
      • 7.2.1. Global Dihydrocodeine by: Application (Value)
        • 7.2.1.1. Cough Suppressant
        • 7.2.1.2. Analgesic
      • 7.2.2. Global Dihydrocodeine by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Injection
      • 7.2.3. Global Dihydrocodeine Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Dihydrocodeine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dihydrocodeine: by Application(USD Million)
  • Table 2. Dihydrocodeine Cough Suppressant , by Region USD Million (2017-2022)
  • Table 3. Dihydrocodeine Analgesic , by Region USD Million (2017-2022)
  • Table 4. Dihydrocodeine: by Route of Administration(USD Million)
  • Table 5. Dihydrocodeine Oral , by Region USD Million (2017-2022)
  • Table 6. Dihydrocodeine Injection , by Region USD Million (2017-2022)
  • Table 7. South America Dihydrocodeine, by Country USD Million (2017-2022)
  • Table 8. South America Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 9. South America Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 10. Brazil Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 11. Brazil Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 12. Argentina Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 13. Argentina Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 14. Rest of South America Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 15. Rest of South America Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 16. Asia Pacific Dihydrocodeine, by Country USD Million (2017-2022)
  • Table 17. Asia Pacific Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 18. Asia Pacific Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 19. China Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 20. China Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 21. Japan Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 22. Japan Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 23. India Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 24. India Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 25. South Korea Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 26. South Korea Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 27. Taiwan Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 28. Taiwan Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 29. Australia Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 30. Australia Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 31. Rest of Asia-Pacific Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 32. Rest of Asia-Pacific Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 33. Europe Dihydrocodeine, by Country USD Million (2017-2022)
  • Table 34. Europe Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 35. Europe Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 36. Germany Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 37. Germany Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 38. France Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 39. France Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 40. Italy Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 41. Italy Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 42. United Kingdom Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 43. United Kingdom Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 44. Netherlands Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 45. Netherlands Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 46. Rest of Europe Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 47. Rest of Europe Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 48. MEA Dihydrocodeine, by Country USD Million (2017-2022)
  • Table 49. MEA Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 50. MEA Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 51. Middle East Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 52. Middle East Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 53. Africa Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 54. Africa Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 55. North America Dihydrocodeine, by Country USD Million (2017-2022)
  • Table 56. North America Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 57. North America Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 58. United States Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 59. United States Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 60. Canada Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 61. Canada Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 62. Mexico Dihydrocodeine, by Application USD Million (2017-2022)
  • Table 63. Mexico Dihydrocodeine, by Route of Administration USD Million (2017-2022)
  • Table 64. Company Basic Information, Sales Area and Its Competitors
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Dihydrocodeine: by Application(USD Million)
  • Table 75. Dihydrocodeine Cough Suppressant , by Region USD Million (2023-2028)
  • Table 76. Dihydrocodeine Analgesic , by Region USD Million (2023-2028)
  • Table 77. Dihydrocodeine: by Route of Administration(USD Million)
  • Table 78. Dihydrocodeine Oral , by Region USD Million (2023-2028)
  • Table 79. Dihydrocodeine Injection , by Region USD Million (2023-2028)
  • Table 80. South America Dihydrocodeine, by Country USD Million (2023-2028)
  • Table 81. South America Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 82. South America Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 83. Brazil Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 84. Brazil Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 85. Argentina Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 86. Argentina Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 87. Rest of South America Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 88. Rest of South America Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 89. Asia Pacific Dihydrocodeine, by Country USD Million (2023-2028)
  • Table 90. Asia Pacific Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 91. Asia Pacific Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 92. China Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 93. China Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 94. Japan Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 95. Japan Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 96. India Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 97. India Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 98. South Korea Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 99. South Korea Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 100. Taiwan Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 101. Taiwan Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 102. Australia Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 103. Australia Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 104. Rest of Asia-Pacific Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 105. Rest of Asia-Pacific Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 106. Europe Dihydrocodeine, by Country USD Million (2023-2028)
  • Table 107. Europe Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 108. Europe Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 109. Germany Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 110. Germany Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 111. France Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 112. France Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 113. Italy Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 114. Italy Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 115. United Kingdom Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 116. United Kingdom Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 117. Netherlands Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 118. Netherlands Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 119. Rest of Europe Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 120. Rest of Europe Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 121. MEA Dihydrocodeine, by Country USD Million (2023-2028)
  • Table 122. MEA Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 123. MEA Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 124. Middle East Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 125. Middle East Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 126. Africa Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 127. Africa Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 128. North America Dihydrocodeine, by Country USD Million (2023-2028)
  • Table 129. North America Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 130. North America Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 131. United States Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 132. United States Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 133. Canada Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 134. Canada Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 135. Mexico Dihydrocodeine, by Application USD Million (2023-2028)
  • Table 136. Mexico Dihydrocodeine, by Route of Administration USD Million (2023-2028)
  • Table 137. Research Programs/Design for This Report
  • Table 138. Key Data Information from Secondary Sources
  • Table 139. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dihydrocodeine: by Application USD Million (2017-2022)
  • Figure 5. Global Dihydrocodeine: by Route of Administration USD Million (2017-2022)
  • Figure 6. South America Dihydrocodeine Share (%), by Country
  • Figure 7. Asia Pacific Dihydrocodeine Share (%), by Country
  • Figure 8. Europe Dihydrocodeine Share (%), by Country
  • Figure 9. MEA Dihydrocodeine Share (%), by Country
  • Figure 10. North America Dihydrocodeine Share (%), by Country
  • Figure 11. Global Dihydrocodeine share by Players 2022 (%)
  • Figure 12. Global Dihydrocodeine share by Players (Top 3) 2022(%)
  • Figure 13. Global Dihydrocodeine share by Players (Top 5) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Teofarma (Italy) Revenue, Net Income and Gross profit
  • Figure 16. Teofarma (Italy) Revenue: by Geography 2022
  • Figure 17. Mundipharma (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. Mundipharma (United Kingdom) Revenue: by Geography 2022
  • Figure 19. Napp Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. Napp Pharmaceuticals (United Kingdom) Revenue: by Geography 2022
  • Figure 21. Aspen Pharmacare (South Africa) Revenue, Net Income and Gross profit
  • Figure 22. Aspen Pharmacare (South Africa) Revenue: by Geography 2022
  • Figure 23. Martindale-Hubbell (United States) Revenue, Net Income and Gross profit
  • Figure 24. Martindale-Hubbell (United States) Revenue: by Geography 2022
  • Figure 25. Duopharma Biotech Berhad (Malaysia) Revenue, Net Income and Gross profit
  • Figure 26. Duopharma Biotech Berhad (Malaysia) Revenue: by Geography 2022
  • Figure 27. Wockhardt (India) Revenue, Net Income and Gross profit
  • Figure 28. Wockhardt (India) Revenue: by Geography 2022
  • Figure 29. Auden Mckenzie Pharma (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. Auden Mckenzie Pharma (United Kingdom) Revenue: by Geography 2022
  • Figure 31. WraSer (United States) Revenue, Net Income and Gross profit
  • Figure 32. WraSer (United States) Revenue: by Geography 2022
  • Figure 33. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2022
  • Figure 35. Global Dihydrocodeine: by Application USD Million (2023-2028)
  • Figure 36. Global Dihydrocodeine: by Route of Administration USD Million (2023-2028)
  • Figure 37. South America Dihydrocodeine Share (%), by Country
  • Figure 38. Asia Pacific Dihydrocodeine Share (%), by Country
  • Figure 39. Europe Dihydrocodeine Share (%), by Country
  • Figure 40. MEA Dihydrocodeine Share (%), by Country
  • Figure 41. North America Dihydrocodeine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Teofarma (Italy)
  • Mundipharma (United Kingdom)
  • Napp Pharmaceuticals (United Kingdom)
  • Aspen Pharmacare (South Africa)
  • Martindale-Hubbell (United States)
  • Duopharma Biotech Berhad (Malaysia)
  • Wockhardt (India)
  • Auden Mckenzie Pharma (United Kingdom)
  • WraSer (United States)
  • GlaxoSmithKline (United Kingdom)
Additional players considered in the study are as follows:
G.L. Pharma (Austria) , Daiichi Sankyo (Japan) , Fuso Pharmaceutical (Japan)
Select User Access Type

Key Highlights of Report


Dec 2023 213 Pages 67 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dihydrocodeine Market Quantitative research analysis
Global Dihydrocodeine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Dihydrocodeine market are Teofarma (Italy), Mundipharma (United Kingdom), Napp Pharmaceuticals (United Kingdom), Aspen Pharmacare (South Africa), Martindale-Hubbell (United States), Duopharma Biotech Berhad (Malaysia), Wockhardt (India), Auden Mckenzie Pharma (United Kingdom), WraSer (United States) and GlaxoSmithKline (United Kingdom), to name a few.
"High Demand for Dihydrocodeine with Improved Feature" is seen as one of major influencing trends for Dihydrocodeine Market during projected period 2022-2028.

Know More About Global Dihydrocodeine Market Report?

Have a Query? Click Here

Other Related Reports

Amitryptyline Comprehensive Study by Patient Type (Adult, Pediatric), By Strength (10 mg tablets, 25 mg tablets, 50 mg tablets, 75 mg tablets, 100 mg tablets, 150 mg tablets), Distribution Channel (H...
$ 3650
Sultamicillin Comprehensive Study by Type (Patent, Generic), Application (Complicated Urinary Tract Infection (CUTI), Complicated Intra-Abdominal Infections (CIAI), Blood Stream Infections (BSI), Clo...
$ 3750
Ambrisentan Drug Comprehensive Study by Impairment Type (Renal Impairment, Hepatic Impairment), End-Use (Hospitals, Specialty Drug Store), Strength (5mg, 10mg) Players and Region - Global Market Outl...
$ 3500
Lexapro Comprehensive Study by Application (Depression, Obsessive-Compulsive Disorder, Panic Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder), Distribution Channel (Online, Offline), ...
$ 3350
Meloxicam Comprehensive Study by Application (Hospitals, Clinics, Veterinary, Household), Form (Tablets, Injection), Sales Channel (Online, Offline) Players and Region - Global Market Outlook to 2030
$ 3500
Bile Acid Sequestrants Comprehensive Study by Type (Cholestyramine {Questran, Prevalite}, Colestipol {Colestid, Flavored Colestid}, Colesevelam {Welchol}), Application (Hospitals, Households, Clinics...
$ 3450